deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03396952

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma

Sponsor: Merck Sharp & Dohme LLC

Conditions Stage III Cutaneous Melanoma Stage IIIA Cutaneous Melanoma Stage IIIB Cutaneous Melanoma Stage IIIC Cutaneous Melanoma Stage IV Cutaneous Melanoma
Interventions Aspirin Ipilimumab Laboratory Biomarker Analysis Pembrolizumab
Updated 13 times since 2018 Last updated: Sep 19, 2022 Started: Apr 19, 2018 Primary completion: Apr 30, 2020 Completion: Jun 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Stage III Cutaneous Melanoma and Stage IIIA Cutaneous Melanoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 13 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jul 2020 · 13 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jun 2022 · 9 months · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Nov 2022 · 4 months · monthly snapshot~Nov 2022 – ~Jul 2024 · 20 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2022 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jul 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2022 — Jul 2022 [monthly]

    Active Not Recruiting PHASE2

▶ Show 8 earlier versions

  1. Sep 2021 — Jun 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  5. Jun 2019 — Jul 2020 [monthly]

    Recruiting PHASE2

  6. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Feb 2018 — Mar 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations